Selexis signs SURE deal with Alpha Biologics

16 July 2006

Privately-held Swiss biotechnology firm Selexis SA has entered a cooperative agreement with Malaysia-based contract manufacturer Alpha Biologics Sdn Bhd, to develop cell lines using the former's SURE technology platform.

Under the terms of the deal, Alpha will get access to the firm's expertise and the use of SURE which, according to Selexis, "enables fast, stable and high-yield cell lines that produce proteins and antibodies for use in biopharmaceuticals." Financial terms of the accord were not disclosed.

Igor Fisch, chief executive of the Geneva-based company, stated that SURE will "help Alpha Biologics deliver therapeutic proteins for use in preclinical, Phase I and II clinical trials to their customers significantly faster and more cost effectively," noting that "this agreement is the first step of [Selexis'] strategy to enter into the Asian market."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.